PEPtalk
A twice-weekly, AI-hosted podcast on the peptide market. Mondays: deep dives — a fast pulse on the big GLP-1 names plus one molecule unpacked in full. Fridays: the week in review — the biggest stories from the lab, the market, and the regulators, all in about fifteen minutes. Hosted by Jake and Cynthia. For research and informational purposes only — not medical advice.
Episodes
5 episodes
5: Peptalk Deep Dive — Tesamorelin
Last week: Sermorelin, the elegant idea. This week: Tesamorelin - its bigger sibling, and the evidence heavyweight of the growth hormone peptide world. Jake and Cynthia unpack Tesamorelin — the full forty-four amino acid gro...
4: Peptalk Week in Review — October 9, 2026
This week: both Lilly and Novo converged on $499/month cash pricing — and we walk the whole price ladder from list price to TrumpRx to the gray market. Plus: Petrelintide's Phase 2 amylin data (up to 10.7% at 42 weeks with placebo-...
3: Peptalk Deep Dive — Sermorelin
Sermorelin is having a moment. Jake and Cynthia unpack the growth hormone peptide everyone's pivoting to: what it is (a copy of your body's own GHRH signal), how it works (pulsatile, feedback-intact), what the research actually sho...
2: Peptalk Week in Review — October 2, 2026
EASD 2026 in Milan turned into a Lilly showcase — and Jake and Cynthia round up the whole week.Stories this week: (1) Retatrutide's full Phase 3 TRIUMPH-1 data — up to 25% weight loss at 80 weeks, plus knee osteoarthritis an...
Peptalk Pilot: Deep Dive — NAD+
Welcome to Peptalk! In our pilot episode, Jake and Cynthia go deep on NAD+ (nicotinamide adenine dinucleotide) — one of the most talked-about molecules in the peptide world right now, even though it's not technically a peptide at all.We...